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been demonstrated in patients with chronic myelogenous 
leukemia (CML). Allogeneic stem cell transplantation (ASCT) can 
be curative for patients (pts) with CML. It is not known if the 
abnormal BM angiogenesis changes following SCT. We studied 
the effect of SCT on BM microvesseI density (MVD) in CML and 
examined the prognostic value of pre and post ransplant (Tx) 
MVD. Patients and Methods: We evaluated MVD from BM 
samples obtained just prior to and at 3-5 months after ASCT in 
38 CML pts.31 pts each had either pre-Tx or post-Tx biopsies 
and 24 pts had both pre and post Tx biopsies available for com- 
parison. Microvessels were stained using immunohistochemical 
staining for vonWillebrand factor, using a labeled streptavidin- 
biotin peroxidase method. MVD was estimated by determining 
the average number of vessels in 3 hot spots examined at 400x 
magnification. The angiogenesis was graded as low (MVD < 10), 
intermediate (MVD < 20) or high (MVD >= 20). Results: The 
median MVD pre Tx for 31 pts was 14 (4-37); with 13 pts having 
high-grade angiogenesis, 12 intermediate-grade and 6 low-grade. 
The median post Tx MVD in 31 pts was 20 (range 5-36) with 16 
pts having high-grade angiogenesis, 13 intermediate-grade and 2 
low-grade. The median time between biopsies was 4 months 
(range 1-6 months). There was no significant change in the fol- 
lowing Tx (P =0.8, paired t-test). The MVD increased in 12 pts 
(median increase 8), decreased in 10 (median decrease 9) and 
remained unchanged in 2. The pre or post Tx MVD did not pre- 
dict relapse free or overall survival following SCT. The microves- 
sels in the post Tx BM demonstrated striking dilatation compared 
to the pre-Tx marrow. Conclusion: BM angiogenesis seen in 
CML does not change significantly following allogeneic SCT. 
These results are consistent with what we have observed in 
patients with nmltiple myeloma receiving high dose or conven- 
tional therapy and also with other reports. It is possible that per- 
sistent vessels may serve as a nidus for tumor relapse, however we 
were not able to demonstrate such an effect in our small group. 
This data provide further evidence against using regression of 
angiogenesis a a marker of therapeutic response, even in the con- 
text of anti-angiogenic therapy. 
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infections remains amain cause of morbidity and mortality after 
allo-BMT. Herein we describe our data concerning infections 
incidence until D+100 after BMT. We retrospectively reviewed 
98 patients transplanted from i2/94 to 04/02 with an HLA-identi- 
cal (n-96), 1-HLA allele mismatch (n=l) or singeneic (n=l) sibling 
donor. Graft source was bone marrow in 88 patients. Median fol- 
low-up was 3 years. Median age was 31 years. Seventy-six patients 
had malignancies (CML 45, ALL/AML 27, MDS 4). Eight-eight 
patients were CMV positive. GV}tD prophylaxis was cyclosporine 
+ methotrexate in 94 patients. Uni- and multivariate analysis were 
performed with Kaplan-Meier/log rank and Cox models respec- 
tively. Transplant-related mortality (TRM) and overall survival 
(OS) were 24% (100 days) and 54% (5 years). Acute grade 2-4 
GVt-ID incidence was 32%. Fifty-four patients presented at least 
one episode of a severe bacterial infection (septicemia, septic 
shock, and pneumonia), with a cumulative incidence of 56% until 
D+100. Most frequent bacteria isolated were Staphylococcus sp. 
(n=53), E. coli (n=7) and Klebsiella sp. (n=6). In univariate analy- 
sis, no variable influencing incidence of bacterial infections, how- 
ever, there was a tendency of less bacterial infections with a higher 
nucleated cell dose graft (p=0.11). Thirty-five patients presented 
at least one episode of CMV reactivation with a cmnulative inci- 
dence of 36%. Six patients presented a CMV disease. In multivari- 
ate analysis, presence of acute GVHD grade 2-4 (HR=2.8; CI95: 
1.43-5.46; P=0.003) and recipient age more than 18 years 
(HR=0.09; CI95: 0.01-0.64; P=0.02) were associated with a higher 
incidence of CMV infection/disease. Only three patients present- 
ed a proven or probable invasive fungal infection: 1 candidemia, 1 
Aspergillus p. infection and 1 Fusarium sp. infection until D+100. 
The incidence of bacterial and CMV infections were comparable 
to the literature. On the other hand, despite use of a relatively 
lower dose of fluconazole, incidence of fungal infection was signif- 
icanty lower than expected. In our experience, use of low-dose flu- 
conazole (200mg/d) is sufficient o provide adequate prophylaxis 
for fungal infections, decreasing BMT costs. Low incidence of 
mold infections might be explained by factors other than flucona- 
zole use. 
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Search speed and monetary resources can be minimized by 
inserting a DNA based high resolution typing before r questing 
an unrelated stem ceil donor for confirmatory t ping. Therefore 
the DICMS offers the possibility to request high resolution typing 
class I and II since 1992 (at least on four digits leveI). These typ- 
ings are performed with new drawn blood samples and not with 
"stored samples", because we think that donors hould be aware of 
the importance to become apotential stem cell donor soon. With 
the introduction of optimized software and changing the workfiow 
in 2000, the turnaround time from donor contact o the transmis- 
sion of the typing results could be halved from over 20 to about 
10-13 days. The results of the high resolution typings give a very 
precise preselection of donors for an allogenic stem ceil transplan- 
tation. So the donor selected for confirmatory typing after a 
request for high resolution typing is more propable to be the suit- 
able donor. We observe asteadily increasing number of high reso- 
lution typing requests that over-strides the increasing number of 
the confirmatory t pings. High resolution typings and the return- 
ing of the confirmatory typing results by the search centers 
heighten the quality of our donor data base, reduce the workload 
for the search centers and accelerate donor searches in the future. 
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The long term prognosis for persons affected with Adult t-cell 
leukemia/lymphoma associated with HTLV -1 disease is dismal. 
We report a case in which a patient is without evidence of disease 
at 18 months after peripheral blood stem ceil transplant. Her 
brother was her matched onor. She was treated with Fludarabine 
and Busulfex conditioning regimen prior to transplant. She is thiry 
nine years old, African American, diagnosed in November 2000. 
She presented with palpable adenopathy, hepatomegaly, elevated 
WBC of forty-four thousand and eight nine percent lymphocytes, 
hypercalcemia, elevated LDH, pleural effilsion, pericardial effu- 
sion and multiple areas of adenopathy in her chest. HTLV 1 anti- 
body was reactive. Bone marrow biopsy and thoracentesis were 
both consistent with ATLL. Complex chromosome abnormalities 
were present including trisomy 3 and 7. She received 2 cycles of 
adriamycin, VP-16, dexamethasone with decrease in adenopathy 
and was brought o transplant after passing the requisite pretrans- 
plant organ testing. She received 16 doses of high dose Busulfex 
per pharmacokinetic dosing every six hours, Fludarabine at 
40mg/m2, one dose daily for 5 consecutive days, and antithymo- 
cyte globulin 15mg/kg for four doses. Her graft versus host dis- 
ease prevention included long course methotrexate and 
cyclosporine. Evaluations at 100 days, 200 days, 1 year and 18 
months show no radiographic evidence of disease. FISH studies 
consistently show 100% male donor chromosomes. Bone marrow 
aspirate and biopsy at one year shows normal tissue morphology 
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